Real-World Data for Real-World Patients: A Broadened Lens to Informed Decision-Making in Venous Thromboembolism
Premiere Date: Tuesday, June 8, 2021This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, June 8, 2022
Note: Credit Is No Longer Available
 | Gregory Piazza, MD, MS (Moderator) Director, Vascular Medicine Section Brigham and Women's Hospital Associate Professor of Medicine Cardiovascular Medicine Harvard Medical School Boston, MA |
 | Javid J. Moslehi, MD Associate Professor of Medicine Director, Cardio-Oncology Program Co-Director, Vanderbilt Program for Optimizing Immuno-Oncology Therapy (V-POINT) Division of Cardiovascular Medicine Vanderbilt University Medical Center Nashville, TN |
Venous thromboembolism (VTE), comprised of deep vein thrombosis (DVT) and pulmonary embolism (PE), affects up to 900,000 individuals in the US each year, leading to nearly 100,000 annual VTE-related deaths. It is the most preventable cause of death in hospitalized patients and its incidence will continue to rise with aging populations and as people live longer with chronic conditions. Anticoagulants can reduce the risk for thrombus extension, recurrence, and embolization and prevent post-thrombotic syndrome, and randomized clinical trials (RCTs) have provided established safety and efficacy data on the available treatments, but there is a need for health care practitioners to understand their efficacy through the lens of real-world data (RWD) and real-world evidence (RWE). Consideration and appropriate clinical application of RWD/RWE complements findings from RCTs by including information on patient populations and clinical scenarios not studied in RCTs. This can improve both quality of care and patient outcomes.
This CMEOCast podcast will compare the safety and efficacy of DOACs versus VKAs based on RWD, its methodology, study design, and assessment considerations, and focus on integrating this data into practice to individualize treatment decision-making for patients with VTE.
At the end of this CE activity, participants should be able to:
- Compare the safety and efficacy of DOACs versus VKAs based on RWD.
- Integrate RWD into practice to individualize treatment decision-making for patients with VTE.
- Apply knowledge of RWD methodology, study design, and assessment considerations to the interpretation and application of the data to clinical practice.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Compare the safety and efficacy of DOACs versus VKAs based on RWD.
- Explain how to integrate RWD into practice to individualize treatment decision-making for patients with VTE.
- Describe RWD methodology, study design, and assessment considerations for the interpretation and application of the data to clinical practice.
Supported by educational grants from the Bristol Myers Squibb and Pfizer Alliance and Janssen Pharmaceuticals, Inc. administered by Janssen Scientific Affairs, LLC.
VTE specialists, pulmonologists, hematologist-oncologists, emergency physicians, internists, family practitioners, PAs, nurse practitioners, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.005 CEUs) Universal Activity Number:
Enduring: JA0007185-0000-21-114-H01-P
Type: Knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Enduring material
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Piazza reports that he receives grants from Amgen Inc.; Bayer; Bristol Myers Squibb and Pfizer Alliance; Boston Scientific Corporation; Janssen Pharmaceuticals, Inc.; and Portola Pharmaceuticals, Inc.
Dr. Moslehi reports that he receives research grants from Pfizer Inc. and Bristol Myers Squibb Company. He consults for Acceleron Pharma, Inc.; Amgen Inc.; ARIAD Pharmaceuticals, Inc.; AstraZeneca; Audentes Therapeutics; Boehringer Ingelheim; Boston Biomedical, Inc.; Bristol-Myers Squibb Company; Cytokenetics, Inc.; Daiichi Sankyo, Inc.; Decphera Pharmaceuticals, Inc.; GlaxoSmithKline; Heat Biologics, Inc.; ImmunoCore; Incyte; Intrexon; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; MyoKardia; Myovant Sciences; Nektar; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmacyclics; Redux; Regeneron Pharmaceuticals Inc.; Rgenix, Inc.; Stemcentrx; Takeda Pharmaceutical Company Limited/Millennium Pharmaceuticals, Inc.; Verastem, Inc.; and Vertex Pharmaceuticals Incorporated.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Warren Beckman (planning committee) has no disclosures to report.
Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PD-060-060821-90
